Asset Details
Do you wish to reserve the book?
Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival
Do you wish to request the book?
Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival
2018
Overview
Purpose
Considering the unmet need for novel molecular tumor markers capable of improving prostate cancer (CaP) patients’ management along with the fruitful results regarding the future use of ribonucleases (RNases) as molecular diagnostic and prognostic markers in CaP, we aimed to study the expressional profile of
RNase κ
in CaP and BPH and to investigate its clinical significance in CaP.
Methods
Total RNA was extracted from 212 prostatic tissue samples (101 BPH and 111 CaP) and, following cDNA synthesis, quantitative real-time PCR (qPCR) was performed for the expressional quantification of
RNase κ
. Extensive statistical analysis, including bootstrap resampling, was performed to investigate the differential expression of
RNase κ
in patients with BPH and CaP and its associations with patients’ clinicopathological and survival data.
Results
RNase κ
was significantly downregulated (
P
= 0.002) in CaP patients compared to BPH ones.
RNase κ
overexpression was associated with decreased risk of CaP development and can discriminate between CaP and BPH independently of serum PSA levels (crude odds ratio = 0.93,
P
= 0.001).
RNase κ
upregulation was also associated with less advanced (
P
= 0.018) and less aggressive (
P
= 0.001) tumors as well as with longer progression-free survival (PFS) (
P
= 0.003). Finally univariate bootstrap Cox regression confirmed that
RNase κ
was associated with favorable prognosis (HR = 0.85,
P
= 0.002).
Conclusions
RNase κ
is a biomarker of favorable prognosis in CaP, which is significantly associated with less advanced and aggressive disease, as well as with enhanced PFS.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Endoribonucleases - genetics
/ Endoribonucleases - metabolism
/ Humans
/ Male
/ Medicine
/ Oncology
/ Original Article – Clinical Oncology
/ Original – Clinical Oncology
/ Prostatic Hyperplasia - enzymology
/ Prostatic Hyperplasia - genetics
/ Prostatic Hyperplasia - mortality
/ Prostatic Hyperplasia - surgery
/ Prostatic Neoplasms - enzymology
/ Prostatic Neoplasms - genetics
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - surgery
/ RNA
/ Survival
/ Tumors
